ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $0

      Shares

      0

      % of Portfolio

      0.00%

      Average Buy Price

      $107

      Avg closing price
      Price range

      21 Paul Tudor Jones II Natera Trades

      Paul Tudor Jones II's position in Natera is currently worth $420k. That's 0.00% of their equity portfolio (1299th largest holding). The first Natera trade was made in Q1 2016. Since then Paul Tudor Jones II bought shares fourteen more times and sold shares on eleven occasions. The stake costed the investor $370k, netting the investor a gain of 14% so far.

      Avg closing price
      Price range
      Sold -59.6k shares Q1 2025
      Avg closing price $161.15
      Price range $132.63 - $177.00
      Increased shares by 2.6% (+1.51k shares) Q4 2024
      Avg closing price $146.56
      Price range $117.67 - $174.00
      Increased shares by 43.5% (+17.6k shares) Q3 2024
      Avg closing price $114.82
      Price range $97.75 - $129.67
      New holding (+40.5k shares) Q2 2024
      Avg closing price $101.57
      Price range $85.28 - $112.60
      Sold -70.5k shares Q1 2024
      Avg closing price $75.21
      Price range $59.21 - $92.90
      New holding (+70.5k shares) Q4 2023
      Avg closing price $49.96
      Price range $37.55 - $62.64
      Sold -16.1k shares Q3 2023
      Avg closing price $51.00
      Price range $43.40 - $62.52
      New holding (+16.1k shares) Q2 2023
      Avg closing price $51.01
      Price range $47.08 - $55.16
      Sold -71.8k shares Q1 2023
      Avg closing price $47.99
      Price range $36.57 - $58.29
      Increased shares by 62.4% (+27.6k shares) Q4 2022
      Avg closing price $41.20
      Price range $34.17 - $47.91
      New holding (+44.2k shares) Q3 2022
      Avg closing price $47.60
      Price range $36.93 - $56.68
      Sold -28.6k shares Q2 2022
      Avg closing price $37.02
      Price range $28.13 - $44.54
      New holding (+28.6k shares) Q1 2022
      Avg closing price $60.09
      Price range $30.32 - $91.33
      Sold -1.94k shares Q4 2021
      Avg closing price $103.78
      Price range $86.26 - $119.00
      Sold 98.0% shares (-94.3k shares) Q3 2021
      Avg closing price $114.62
      Price range $100.17 - $126.36
      Increased shares by 400.3% (+77k shares) Q2 2021
      Avg closing price $102.30
      Price range $86.05 - $119.72
      Sold 61.2% shares (-30.4k shares) Q1 2021
      Avg closing price $109.57
      Price range $91.47 - $124.36
      Increased shares by 127.8% (+27.8k shares) Q4 2020
      Avg closing price $83.55
      Price range $66.66 - $111.74
      New holding (+21.8k shares) Q3 2020
      Avg closing price $56.85
      Price range $45.89 - $72.67
      Sold -10.3k shares Q3 2016
      Avg closing price $11.27
      Price range $9.53 - $13.28

      News about Natera Inc and Paul Tudor Jones II

      Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

      Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

      AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study ...

      businesswire.com businesswire.com, over 1 year ago
      Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera? in Stage II Colorectal Cancer

      Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera? in Stage II Colorectal Cancer

      AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the F¨¦d¨¦ration Fr...

      businesswire.com businesswire.com, over 1 year ago
      Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera? in Colorectal Cancer | NTRA Stock News

      Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera? in Colorectal Cancer | NTRA Stock News

      Natera, Inc., a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized,

      Stock Titan Stock Titan, about 2 years ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×